Press releasePRNewswire
Northwest Biotherapeutics
NWBO · OTC
$0.1645+$0.0094 (+6.06%)TodayMarket closed ·
Prev close $0.1551
Latest news
- Press releasePRNewswire
Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference
- Press releasePRNewswire
Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company
- Press releasePRNewswire
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
- Press releasePRNewswire
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
- Press releaseGlobe Newswire
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
- Press releaseGlobe Newswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
- Press releasePRNewswire
Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform
- Press releasePRNewswire
Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic
- Press releasePRNewswire
Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility
- Press releasePRNewswire
Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed
- Press releasePRNewswire
Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.
- Press releasePRNewswire
Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
- Press releasePRNewswire
Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments
- Press releasePRNewswire
Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.